VANCOUVER, BC, June 5, 2023 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General…

Source

Previous articleAlgernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
Next articleCOMPASS Pathways’ key patents upheld by the US Patent and Trademark Office